MSB 12.1% 55.5¢ mesoblast limited

"Shorting of healthcare stocks, including speculative biotech...

  1. 16,379 Posts.
    lightbulb Created with Sketch. 7935
    "Shorting of healthcare stocks, including speculative biotech stocks, should be completely banned. Forget about the profit motive for a second, but these companies aim to develop products that improve the quality of life of people with acute or chronic illnesses. "

    Novel concept.

    But if the objective here is to maximise the opportunity to develop life-saving medical products and therapies, then what about capping the remuneration packages of the executive involved in these businesses... to, say, a still-generous $500k pa for CEOs (as opposed to $2m pa) and an industry-norm $120kpa for non-executive chairs of boards of directors (as opposed to $350kpa), to bring their compensation to levels in line with other listed companies of similar size and complexity?

    All in the interests of maximising the resources of these "protected species" companies towards the business of finding cures.

    And on that note, what about the issuance of in-the-money or at-the-money options to company executives? Should that also be banned? Or should managers of these sorts of businesses be perpetually in the position of all-upside, no-downside?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
7 99223 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 44000 4
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 28/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.